抗VEGF制剂及其联合应用治疗脉络膜新生血管研究进展  

Research advances in anti-VEGF and combination therapy for choroidal neovascularization

作　　者：赵秀娟[1] 樊映川[2] 

机构地区：[1]泸州医学院临床医学院眼科,四川省泸州市646000 [2]四川省医学科学院四川省人民医院眼科,四川省成都市610072

出　　处：《眼科新进展》2011年第3期297-300,共4页Recent Advances in Ophthalmology

摘　　要：年龄相关性黄斑变性是65岁以上人群不可逆视力损伤的重要原因之一。严重的视力丧失发生在有脉络膜新生血管发展的湿性年龄相关性黄斑变性。血管内皮生长因子(vascular endothelial growth facter,VEGF)是导致脉络膜新生血管形成的主要因素之一,目前多种抗VEGF药物已经被应用于眼科,并显示出良好的疗效。现对研发的多种抗VEGF药物及其联合应用的临床研究进行综述。Age-related macular degeneration is the leading cause of irreversible blindness in people over 65 years old.Severe loss of vision occurs in exudative age-related macular degeneration with the development of choroidal neovascularization.Vascular endothelial growth factor（VEGF） is implicated as the key factor in the provocation of choroidal neovascularization.Therefore,various anti-VEGF agents have been used in the domain of ophthalmology,and showed good effect.This article reviews the clinical study of anti-VEGF agents and combination therapy.

关 键 词：脉络膜新生血管 抗血管内皮生长因子制剂 联合治疗 

分 类 号：R773.4[医药卫生—眼科]